After the observation of encouraging activity with pertuzumab and trastuzumab combination therapy in patients with HER2-positive MBC who had experienced progression on trastuzumab-based therapy, 18 ...

Pertuzumab and pertuzumab/trastuzumab in breast cancer: now minor added benefit Advantages in overall survival and recurrence often only become apparent after a longer period of time – current ...

Patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination of pertuzumab, trastuzumab and chemotherapy ...

The DESTINY-Breast09 trial randomized 1157 patients with locally advanced or metastatic HER2-positive breast cancer to receive either trastuzumab deruxtecan plus pertuzumab (n = 383), trastuzumab ...

Trastuzumab and pertuzumab are 2 cancer drugs given together. It’s used to treat early, locally advanced and secondary breast cancer that is HER2 positive. You pronounce trastuzumab as ...

Participants in the pertuzumab arm received: Docetaxel 75-100 mg/m 2 every three weeks for six cycles or until progression; Herceptin 8 mg/kg loading dose followed by 6 mg/kg every three weeks ...

In addition, CLEOPATRA, a Phase III study evaluating the efficacy and safety profile of pertuzumab and Herceptin plus chemotherapy as a first-line regimen in people with HER2-positive metastatic ...

33rd Annual San Antonio Breast Cancer Symposium SAN ANTONIO — Addition of trastuzumab and pertuzumab to docetaxel was associated with a pathological complete response rate of more than 45% in ...

Median duration of follow-up was nearly 2.5 years (29.2 months). As of the data cut-off, 302 (39.6%) patients remained on treatment, 174 in the ENHERTU plus pertuzumab arm and 128 in the THP arm.

Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor ...

-- Phase II Study Evaluating a Novel Targeted Combination Regimen Showed Promising Results in the Neoadjuvant (Pre-surgery) Setting -- SAN ANTONIO, Texas--(BUSINESS WIRE)-- Genentech, a member of the ...

WILMINGTON, Del., June 02, 2025--Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically ...